Cadre Holdings, Inc. (NYSE:CDRE – Get Free Report) CEO Warren B. Kanders sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $33.55, for a total value of $1,677,500.00. Following the sale, the chief executive officer now directly owns 11,682,211 shares in the company, valued at $391,938,179.05. This trade represents a 0.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Cadre Stock Performance
NYSE CDRE traded down $0.11 on Wednesday, reaching $33.44. The stock had a trading volume of 287,416 shares, compared to its average volume of 232,282. The stock has a market cap of $1.36 billion, a P/E ratio of 40.52, a price-to-earnings-growth ratio of 1.98 and a beta of 1.30. Cadre Holdings, Inc. has a 12-month low of $29.18 and a 12-month high of $40.28. The business’s 50-day moving average price is $36.43 and its 200 day moving average price is $34.96. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.96 and a current ratio of 3.01.
Cadre (NYSE:CDRE – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm had revenue of $109.41 million during the quarter, compared to the consensus estimate of $126.27 million. Cadre had a net margin of 6.34% and a return on equity of 12.88%. Cadre’s revenue for the quarter was down 12.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. As a group, equities analysts expect that Cadre Holdings, Inc. will post 1.05 earnings per share for the current year.
Cadre Dividend Announcement
Analyst Upgrades and Downgrades
Separately, Roth Mkm cut their price objective on shares of Cadre from $39.00 to $37.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Cadre has a consensus rating of “Moderate Buy” and a consensus price target of $39.75.
View Our Latest Report on Cadre
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Cadre by 454.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,624 shares of the company’s stock valued at $55,000 after buying an additional 1,331 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Cadre during the 2nd quarter worth $141,000. Franklin Resources Inc. acquired a new position in shares of Cadre during the 3rd quarter worth $208,000. Truist Financial Corp acquired a new stake in shares of Cadre in the second quarter valued at about $209,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in Cadre in the 2nd quarter valued at about $216,000. 43.95% of the stock is currently owned by hedge funds and other institutional investors.
About Cadre
Cadre Holdings, Inc manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products.
Featured Articles
- Five stocks we like better than Cadre
- Airline Stocks – Top Airline Stocks to Buy Now
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Buy P&G Now, Before It Sets A New All-Time High
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Best Aerospace Stocks Investing
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Cadre Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadre and related companies with MarketBeat.com's FREE daily email newsletter.